TP53 and bladder transitional cell carcinoma: In more than 20 tumor types, especially in ACC, BLCA, LIHC, LUAD, PAAD, and UCEC (Supplementary Figure S7), patients with mutated TP53 tended to have higher ANLN expression levels compared to those with wild-type TP53.